Linn Persson Berg
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Linn Persson Berg has a total of 38 co-authors. Here are the top co-authors by number of shared publications:
Tomas Bergström
Department of Infectious Diseases, Institute of Biomedicine, University of Gothenburg, Gothenburg, Sweden
2 shared publicationsA Mörner
Department of Microbiology, The Public Health Agency of Sweden, Solna, Sweden
1 shared publicationA Tegnell
Department of Public Health Analysis and Data Management, The Public Health Agency of Sweden, Solna, Sweden
1 shared publicationAnna Fogdell-Hahn
Department of Clinical Neuroscience, Center for Molecular Medicine, Karolinska Institutet, Stockholm, Sweden
1 shared publication- Barbara Rath
Vaccine Safety Initiative, 10437 Berlin, Germany
1 shared publication Chrysanthi Skevaki
European Society of Clinical Microbiology and Infectious Diseases Study Group for Respiratory Viruses, ESCMID, Basel
1 shared publication
Latest Publications
- 15 October 2025
- Published by Oxford University Press (OUP) in The Journal of Infectious Diseases
- Vol. 232 (Supplement) , S333-S346
The Care Continuum of Patients With Influenza in the Post–COVID-19 Era: A Position Paper
This position paper addresses the evolving care continuum for patients with respiratory viral infections in the context of the post–coronavirus disease 2019 pandemic phase. We emphasize the need to place the patient at the center of attention from the first signs of influenza-like illness to recovery. Current practices have revealed several deficiencies, such as timely access to healthcare, fragmentation of care, and inadequate follow-up instructions. This article proposes means to address these deficiencies and discusses diagnostic and management considerations for patients with suspected influenza infection.
- 15 October 2025
- Published by Oxford University Press (OUP) in The Journal of Infectious Diseases
- Vol. 232 (Supplement) , S333-S346
The Care Continuum of Patients With Influenza in the Post–COVID-19 Era: A Position Paper
This position paper addresses the evolving care continuum for patients with respiratory viral infections in the context of the post–coronavirus disease 2019 pandemic phase. We emphasize the need to place the patient at the center of attention from the first signs of influenza-like illness to recovery. Current practices have revealed several deficiencies, such as timely access to healthcare, fragmentation of care, and inadequate follow-up instructions. This article proposes means to address these deficiencies and discusses diagnostic and management considerations for patients with suspected influenza infection.
- Open Access
- 27 July 2022
- Published by BMJ in BMJ Neurology Open
- Vol. 4 (2) , e000271
Serum IgG levels to Epstein-Barr and measles viruses in patients with multiple sclerosis during natalizumab and interferon beta treatment
Background: Patients with multiple sclerosis (MS) demonstrate higher seroprevalence of Epstein-Barr virus (EBV) and increased anti-EBV IgG levels in serum compared with healthy controls. Intrathecal antibody production to measles virus (MeV) is a common finding in patients with MS. Objective: To measure serum IgG reactivity to EBV glycoprotein 350 (gp350) and MeV nucleocapsid protein (NCORE) in patients with MS and healthy controls and to determine if reactivity changed in patients during interferon beta (IFNβ) and/or natalizumab (NAT) treatment. A secondary aim was to determine the seroprevalence of EBV in patients and controls. Methods: Patients with MS (n=728) were included from the Swedish pharmacovigilance study for NAT. Paired serum samples from 714 patients drawn before and during NAT treatment and paired samples from 170 patients during prior IFNβ treatment were analysed. In total, 156 patients were included in both groups. Samples from 144 matched blood donors served as controls. Indirect ELISA was applied using recombinant EBVgp350 and MeV NCORE as antigens. EBVgp350 IgG seronegative samples were also analysed using EBV nuclear antigen 1 and viral capsid antigen (VCA). Results: Patients with MS showed higher serum levels of anti-EBVgp350 and anti-MeV NCORE IgG compared with controls. During NAT treatment, the levels of anti-EBVgp350 and anti-MeV NCORE IgG declined, compared with the relatively stable levels noted during prior IFNβ treatment. Ten patients failed to demonstrate anti-EBVgp350 IgG but did show detectable anti-VCA IgG, indicating EBV seropositivity. In contrast, 10/144 controls were EBV seronegative. Conclusions: Treatment with NAT, which is considered a selective immunosuppressive agent with a compartmentalised effect on the central nervous system, appeared to be associated with a moderate decrease in circulating IgG levels to EBVgp350 and MeV NCORE. All patients with MS were EBV IgG seropositive, supporting the potential role of EBV in the pathogenesis of MS.
- 27 July 2022
- Published by BMJ in BMJ Neurology Open
- Vol. 4 (2) , e000271
Open AccessSerum IgG levels to Epstein-Barr and measles viruses in patients with multiple sclerosis during natalizumab and interferon beta treatment
Background: Patients with multiple sclerosis (MS) demonstrate higher seroprevalence of Epstein-Barr virus (EBV) and increased anti-EBV IgG levels in serum compared with healthy controls. Intrathecal antibody production to measles virus (MeV) is a common finding in patients with MS. Objective: To measure serum IgG reactivity to EBV glycoprotein 350 (gp350) and MeV nucleocapsid protein (NCORE) in patients with MS and healthy controls and to determine if reactivity changed in patients during interferon beta (IFNβ) and/or natalizumab (NAT) treatment. A secondary aim was to determine the seroprevalence of EBV in patients and controls. Methods: Patients with MS (n=728) were included from the Swedish pharmacovigilance study for NAT. Paired serum samples from 714 patients drawn before and during NAT treatment and paired samples from 170 patients during prior IFNβ treatment were analysed. In total, 156 patients were included in both groups. Samples from 144 matched blood donors served as controls. Indirect ELISA was applied using recombinant EBVgp350 and MeV NCORE as antigens. EBVgp350 IgG seronegative samples were also analysed using EBV nuclear antigen 1 and viral capsid antigen (VCA). Results: Patients with MS showed higher serum levels of anti-EBVgp350 and anti-MeV NCORE IgG compared with controls. During NAT treatment, the levels of anti-EBVgp350 and anti-MeV NCORE IgG declined, compared with the relatively stable levels noted during prior IFNβ treatment. Ten patients failed to demonstrate anti-EBVgp350 IgG but did show detectable anti-VCA IgG, indicating EBV seropositivity. In contrast, 10/144 controls were EBV seronegative. Conclusions: Treatment with NAT, which is considered a selective immunosuppressive agent with a compartmentalised effect on the central nervous system, appeared to be associated with a moderate decrease in circulating IgG levels to EBVgp350 and MeV NCORE. All patients with MS were EBV IgG seropositive, supporting the potential role of EBV in the pathogenesis of MS.
- Open Access
- 1 October 2021
- Published by Elsevier in International Journal of Infectious Diseases
- Vol. 111, 92-98
Severe chickenpox disease and seroprevalence in Sweden – implications for general vaccination
- 1 October 2021
- Published by Elsevier in International Journal of Infectious Diseases
- Vol. 111, 92-98
Open AccessSevere chickenpox disease and seroprevalence in Sweden – implications for general vaccination
- Open Access
- 1 October 2020
- Published by Elsevier in Journal of Virological Methods
- Vol. 284, 113927
Recombinant Epstein-Barr virus glycoprotein 350 as a serological antigen
- 1 October 2020
- Published by Elsevier in Journal of Virological Methods
- Vol. 284, 113927
Open AccessRecombinant Epstein-Barr virus glycoprotein 350 as a serological antigen
- Open Access
- 10 July 2017
- Published by Springer Nature in Journal of Neuroinflammation
- Vol. 14 (1) , 1-11
CXCL11 production in cerebrospinal fluid distinguishes herpes simplex meningitis from herpes simplex encephalitis
The closely related herpes simplex viruses 1 and 2 can cause inflammations of the central nervous system (CNS), where type 1 most often manifest as encephalitis (HSE), and type 2 as meningitis (HSM). HSE is associated with severe neurological complications, while HSM is benign in adults. We proposed that studying the chemokine and cytokine production in cerebrospinal fluid (CSF) and serum could indicate why two closely related viruses exhibit different severity of their accompanied CNS inflammation. Secretion patterns of 30 chemokines and 10 cytokines in CSF of adult patients with acute HSE (n = 14) and HSM (n = 20) in the initial stage of disease were analyzed and compared to control subjects without viral central nervous system infections and to levels in serum. Most measured chemokines and cytokines increased in CSF of HSE and HSM patients. Overall, the CSF chemokine levels were higher in CSF of HSM patients compared to HSE patients. However, only five chemokines reached levels in the CSF that exceeded those in serum facilitating a positive CSF-serum chemokine gradient. Of these, CXCL8, CXCL9, and CXCL10 were present at high levels both in HSE and HSM whereas CXCL11 and CCL8 were present in HSM alone. Several chemokines were also elevated in serum of HSE patients but only one in HSM patients. No chemokine in- or efflux between CSF and serum was indicated as the levels of chemokines in CSF and serum did not correlate. We show that HSM is associated with a stronger and more diverse inflammatory response in the CNS compared to HSE in the initial stage of disease. The chemokine patterns were distinguished by the exclusive local CNS production of CXCL11 and CCL8 in HSM. Inflammation in HSM appears to be restricted to the CNS whereas HSE also was associated with systemic inflammation.
- 10 July 2017
- Published by Springer Nature in Journal of Neuroinflammation
- Vol. 14 (1) , 1-11
Open AccessCXCL11 production in cerebrospinal fluid distinguishes herpes simplex meningitis from herpes simplex encephalitis
The closely related herpes simplex viruses 1 and 2 can cause inflammations of the central nervous system (CNS), where type 1 most often manifest as encephalitis (HSE), and type 2 as meningitis (HSM). HSE is associated with severe neurological complications, while HSM is benign in adults. We proposed that studying the chemokine and cytokine production in cerebrospinal fluid (CSF) and serum could indicate why two closely related viruses exhibit different severity of their accompanied CNS inflammation. Secretion patterns of 30 chemokines and 10 cytokines in CSF of adult patients with acute HSE (n = 14) and HSM (n = 20) in the initial stage of disease were analyzed and compared to control subjects without viral central nervous system infections and to levels in serum. Most measured chemokines and cytokines increased in CSF of HSE and HSM patients. Overall, the CSF chemokine levels were higher in CSF of HSM patients compared to HSE patients. However, only five chemokines reached levels in the CSF that exceeded those in serum facilitating a positive CSF-serum chemokine gradient. Of these, CXCL8, CXCL9, and CXCL10 were present at high levels both in HSE and HSM whereas CXCL11 and CCL8 were present in HSM alone. Several chemokines were also elevated in serum of HSE patients but only one in HSM patients. No chemokine in- or efflux between CSF and serum was indicated as the levels of chemokines in CSF and serum did not correlate. We show that HSM is associated with a stronger and more diverse inflammatory response in the CNS compared to HSE in the initial stage of disease. The chemokine patterns were distinguished by the exclusive local CNS production of CXCL11 and CCL8 in HSM. Inflammation in HSM appears to be restricted to the CNS whereas HSE also was associated with systemic inflammation.